retatrutide triple agonist glp-1 gip glucagon phase 3 2025 The Science Behind Retatrutide: A New Hope for Obesity and Diabetes – Prime Lab Peptides Retatrutide—A Game Changer in Obesity

They were primarily prescribed for diabetes at first, but many patients have started to turn to them for additional uses that include cardiovascular health and especially weight loss

It is a triple-hormone receptor agonist peptide that simultaneously activates GLP-1, GIP, and glucagon (GCG) receptors

A 2025 meta-analysis suggested a slightly increased pancreatitis risk overall, but no strong evidence for increased pancreatic cancer, with some nuance around background medications

In clinical research, participants taking tirzepatide had average systolic blood pressure reductions of about 7.4 to 10.6 mm Hg after 36 weeks

The case for at-home devices in this population rests on three legs: (1) general home device efficacy data (Sadick & Harth 2016, Bu et al

J Am Coll Nutr 1994;13:6-21